Clinical vignette: A 76-year-old man consults you for increasing shortness of breath over the past two years and an increasing requirement for home oxygen. A video-assisted thoracoscopic lung biopsy shows findings of usual interstitial pneumonitis, and he has no identifiable cause for pulmonary fibrosis, so he is considered to have idiopathic pulmonary fibrosis (IPF). His diffusing capacity for carbon monoxide (DLCO) is 45% of predicted, and his total lung capacity is 40% of predicted. Because of his advanced age, he is not considered a candidate for lung transplantation. What treatment should you recommend?
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Current therapy
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with no cur rently approved effective therapies. The median survival after diagnosis is approximately three years. For decades, patients with this disease were treated with a variety of cytotoxic and immuno suppressive drugs, but it is now clear that these treatments do more harm than good. Progressive, fatal pulmonary fibrosis also occurs as a consequence of numerous other diseases, including hypersensitivity pneumonitis, rheuma toid arthritis, and scleroderma. The out come of pulmonary fibrosis in these dis eases is not as uniformly grim, and some patients who are not severely affected improve after antigen removal (in the case of hypersensitivity pneumonitis) or immunosuppressive drug treatment. However, once patients with these diseas es develop moderately severe fibrosis and significant impairment of lung function, most have a very high risk of progression and death, with little evidence of ben eficial effect of pharmacologic interven tion. These clinical characteristics indi cate that significant pulmonary fibrosis, whatever the initiating events, might itself predispose patients to progression of the fibrotic process -suggesting the potential existence of one or more feed forward circuits through which tissue fibrosis begets more fibrosis.
Knowledge gap
Recent work from a number of experimen tal systems has implicated tissue stiffness as an important determinant of multiple cell behaviors. In one of the most striking examples, mesenchymal stem cells plated onto soft substrates differentiate into brain cells, cells plated on substrates of intermediate stiffness differentiate into muscle, and cells plated on the stiffest sub strates differentiate into bone (1). These findings suggest that cells must have pre cise mechanisms to detect and appropri ately respond to changes in the stiffness of their immediate surroundings. Previous work has identified examples of this phe nomenon of "mechanotransduction" that are relevant to tissue fibrosis. For example, lung fibroblasts plated on artificial soft substrates are resistant to differentiation into myofibroblasts and make substantial ly less collagen than fibroblasts plated on artificial stiff substrates (2). Furthermore, stiff substrates have been shown to facili tate cellular activation of latent TGFβ through integrins expressed on fibroblasts or epithelial cells (3, 4) . The recently solved crystal structure of the latent complex of TGFβ provided a compelling explanation of how mechanical force applied through integrins by contracting fibroblasts or epithelial cells could cause release of the active TGFβ cytokine from the embrace of its own carboxyterminal fragment, and how tissue stiffness likely facilitates this process (5) . These findings indicate that increased tissue stiffness in the lungs could contribute to fibrosis.
Research advances
In this issue of the JCI, Zhou et al. pro vide new insight into how fibrosis, once established, can beget more fibrosis (6).
They describe a pathway through which tissue stiffness, in the setting of pulmo nary fibrosis, promotes the differentia tion and survival of pulmonary myofibro blasts. This pathway requires the activity of Rhoassociated kinases (ROCK), which is necessary for contraction and force generation in fibroblasts and for down stream actin polymerization. The authors demonstrate that ROCKinduced actin polymerization leads to nuclear translo cation of the transcriptional coactivator, MKL1, which itself plays important roles in promoting the differentiation and sur vival of myofibroblasts. Enhanced survival is mediated at least in part by induction of the wellcharacterized survival factor B cell lymphoma 2 (BCL2). These results suggest several steps that could be tar geted to break the feedforward circuit connecting tissue stiffness with fibrosis progression.
One of the most exciting possibilities, which was directly tested by Zhou et al. (6) , is that pulmonary fibrosis could be treated by inhibition of ROCK. Several potent ROCK inhibitors are already avail able, and one of these, fasudil, has been approved for clinical use in Japan and China and has already been given to a large number of patients for prevention of vasoconstriction after brain injury. Another ROCK inhibitor, Y27932, was previously shown to prevent pulmonary fibrosis in response to bleomycin (7), but in that study, the drug was adminis tered before bleomycin and might have protected against acute lung injury and inflammation. These steps are important in the bleomycin model, but less relevant to patients with ongoing fibrosis. Zhou et al. showed that fasudil could prevent fibrosis even when administered 14 days after bleomycin (6), at which time inflam mation has largely resolved and fibrosis is already present.
ROCK inhibitors such as fasudil could be effective for treating pulmonary fibro sis by more than one mechanism. These drugs have been previously shown to prevent the contraction of lung epithe lial cells that is required for activation of TGFβ by the epithelial αvβ6 integrin. of systemically administered ROCK inhib itors could be limited by the induction of hypotension. One strategy that deserves further consideration for the treatment of pulmonary fibrosis is chemical modifica tion of ROCK inhibitors to slow absorp tion into the bloodstream and increase systemic metabolism -modifications that could enrich for pulmonary effects if the drugs are administered by aerosol directly into the lung. Such a strategy might allow effective treatment of pulmo nary fibrosis while minimizing the risk of systemic toxicity.
